Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xlife Sciences AGXSWX:XLS +3.34%50 Cash-to-Debt is 0.02 as of Dec. 2025, which is at its 10-year median of 0.02. GuruFocus rates XSWX:XLS with a GF Score™ of 50/100 and a GF Value™ of CHF7.15 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,400 Biotechnology companies, Xlife Sciences AG ranks worse than 98.5% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Xlife Sciences AG's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.02.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Xlife Sciences AGcouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Xlife Sciences AG's Cash-to-Debt or its related term are showing as below:
XSWX:XLS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.09
Current: 0.02
During the past 8 years, Xlife Sciences AG's highest Cash to Debt Ratio was 0.09. The lowest was 0.00. And the median was 0.02.
XSWX:XLS's Cash-to-Debt is ranked worse than 98.5% of 1400
companies
in the Biotechnology industry
Industry Median: 6.52
vs XSWX:XLS: 0.02
Xlife Sciences AG (XSWX:XLS) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Xlife Sciences AG Cash-to-Debt Related Terms
Xlife Sciences AG Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSWX:XLS vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a Cash-to-Debt of 0.02 as of Dec. 2025. This is near median its historical median of 0.02. According to the industry distribution chart, Xlife Sciences AG ranks #1379 out of 1400 companies in the Biotechnology industry, placing it in the top 98.5%.
Is Xlife Sciences AG's Cash-to-Debt too high?
Xlife Sciences AG's current Cash-to-Debt of 0.02 is near median its 10-year median of 0.02. The Biotechnology industry median Cash-to-Debt is 6.52. Xlife Sciences AG's value of 0.02 is 99.7% below this industry median. Based on the distribution chart, Xlife Sciences AG ranks #1379 out of 1400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #1379 out of 1400 companies for Cash-to-Debt. This places Xlife Sciences AG in the lower half of its industry. The industry median Cash-to-Debt is 6.52. Xlife Sciences AG's value of 0.02 is 99.7% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 6.52, Xlife Sciences AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.52, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current Cash-to-Debt of 0.02 is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current Cash-to-Debt is 0.02, which is near median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.15, compared to a current price of CHF17.00 — trading 137.8% above its estimated fair value. The current Cash-to-Debt is 0.02, which is near median its 10-year median of 0.02 and 99.7% below the Biotechnology industry median of 6.52. Xlife Sciences AG's overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Cash-to-Debt is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF17.00 is trading 137.8% above its estimated GF Value™ of CHF7.15.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Cash-to-Debt: 0.02 (near median its 10-year median of 0.02)
GF Value™: CHF7.15 vs. price of CHF17.00 (137.8% above fair value)
Industry Position: 99.7% below the Biotechnology median (#1379 of 1400)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score
Get the complete analysis for XSWX:XLS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
